When was CJ Bioscience founded?

CJ Bioscience was founded in 2009.

Where is CJ Bioscience located?

CJ Bioscience is headquartered in Seoul, South Korea.

How many employees does CJ Bioscience have?

As of May 31, 2026, the latest employee count at CJ Bioscience is 73.

Where does CJ Bioscience rank among its competitors?

CJ Bioscience ranks 1685th amongst 3850 active competitors, of which 1296 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of CJ Bioscience?

CJ Bioscience's top competitors include Jazz Pharmaceuticals, BeiGene and Biogen. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

CJ Bioscience - 2026 Company Profile, Team & Competitors

CJ Bioscience is a public company based in Seoul (South Korea), founded in 2009 by Chun Jongsik. It operates as a Developer of microbiome-based therapeutics for multiple diseases. The company has 3850 active competitors, including 1296 funded and 911 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Biogen.

Company Details

Developer of microbiome-based therapeutics for multiple diseases. The company develops live biotherapeutic products for the treatment of cancer, gastrointestinal and neurological disorders. Also, it develops TrueBac ID a genome-based bacterial infection diagnosis solution.

Website: www.cjbioscience.com/
Social
Phone Number: +82 **********

Key Metrics

Founded Year

2009

Location

Seoul, South Korea

Stage

Public

Ranked

1685^th among 3850 active competitors

Employee Count

73 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3656 more

Exit Details

Public

View CJ Bioscience's full profile

CJ Bioscience got listed on Dec 26, 2019.

Click here to take a look at CJ Bioscience's IPO in detail

CJ Bioscience has not raised any funding rounds yet.

The founders of CJ Bioscience is Chun Jongsik.

Here are the details of CJ Bioscience's key team members:

Chun Jongsik: Founder & CEO of CJ Bioscience and founder of 1 other company.

View details of CJ Bioscience's Founder profiles and Board Members

CJ Bioscience's employee count trend

CJ Bioscience has 73 employees as of May 26. Here is CJ Bioscience's employee count trend over the years:

Uncover CJ Bioscience's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CJ Bioscience include Jazz Pharmaceuticals, BeiGene and Biogen. Here is the list of Top 10 competitors of CJ Bioscience, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
1685th	CJ Bioscience 2009, Seoul (South Korea), Public	Developer of microbiome-based therapeutics for multiple diseases	-	-	34/100